Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accounts Payables (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Accounts Payables for 12 consecutive years, with $10.8 million as the latest value for Q1 2026.

  • For Q1 2026, Accounts Payables rose 7.92% year-over-year to $10.8 million; the TTM value through Mar 2026 reached $10.8 million, up 7.92%, while the annual FY2025 figure was $16.6 million, 42.61% up from the prior year.
  • Accounts Payables hit $10.8 million in Q1 2026 for Syndax Pharmaceuticals, down from $16.6 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $17.4 million in Q2 2025 and bottomed at $4.4 million in Q4 2022.
  • Average Accounts Payables over 5 years is $9.8 million, with a median of $10.0 million recorded in 2023.
  • Year-over-year, Accounts Payables decreased 23.27% in 2022 and then skyrocketed 182.28% in 2025.
  • Syndax Pharmaceuticals' Accounts Payables stood at $4.4 million in 2022, then skyrocketed by 128.99% to $10.0 million in 2023, then rose by 16.72% to $11.6 million in 2024, then soared by 42.61% to $16.6 million in 2025, then plummeted by 34.6% to $10.8 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $10.8 million, $16.6 million, and $13.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.